ENGINEERING 3D TISSUE SYSTEMS TO BETTER MIMIC HUMAN BIOLOGY

Similar documents
REIMAGINING DRUG DEVELOPMENT:

Determining the Predictive Validity of 3D Models & Achieving Standardization for Preclinical Efficacy Testing

Figure 1. Few examples of in-vitro models developed using our products

Syringe Pumps. Please contact us for help in selecting the best pump for your application and a free quote.

Nanotechnology and Advanced Materials for more effective Healthcare

Moving Forward: Advantages and Challenges of Closed-Loop Control for Cell-Based Therapies

Course Catalog - Spring 2015

NEXT GENERATION ECM-BASED ALLOGRAFT TECHNOLOGY:

8. Clinical Trial Assessment Phase II

European Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York

Tissue Engineered Medical Products

3D In Vitro Living Systems for Biological Application

Stem Cells and Regenerative Medicine

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

Abstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2

Peptide libraries: applications, design options and considerations. Laura Geuss, PhD May 5, 2015, 2:00-3:00 pm EST

3D Cell Culture Product Intro. Bio-Byblos Biomedical

Clinically Relevant Dissolution Specifications: FDA Perspective and Initiatives

Research and Innovation in Drug Discovery and Diagnostics

Department of Metallurgy and Materials Engineering, Katholieke Universiteit Leuven, B Leuven, Belgium; 2

AIT Austrian Institute of Technology

Horizon 2020 funding opportunities for Regenerative Medicine ( ) Rudolf Fryček, PhD.

Cell Culture Flasks DATA SHEET

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

The Challenge of Pricing Combination Therapies

Mitigating Commercial Risks in Continuous Manufacturing Drug Product

Comments from the FDA Working Group on SUBGROUP ANALYSES. Estelle Russek-Cohen, Ph.D. U.S. Food and Drug Administration Center for Biologics

Konica Minolta to Acquire Invicro (US)

March 6, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

Microfluidic Platform for Culture and Live Cell Imaging of Cellular Microarrays

Baek, Kyung-min. Recombinant Protein Products Division. Ministry of Food and Drug Safety

The importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016

Technology Development Funding Program Round 3

Freshman/Sophomore Junior Senior

Passive Immunization Trials to Inform Vaccine Design

Global Development Challenges: Classical and Advanced Therapy Medicinal products

Regeneration of spinal cord injury (SCI) : What we know so far. By: Kendra Michaud

Nanoimprinting in Polymers and Applications in Cell Studies. Albert F. YEE Chemical Engineering & Materials Science UC Irvine

Vevo The Ultimate Preclinical Imaging Experience

GMO Technology Conference

Reduce costs of the early drug development process Increase probality of developing drugs that enter late clinical phases

THE NATURAL CHOICE FOR CELL CULTURE

Regulatory Pathways for Rare Diseases

Structural Vacuum Insulation Panels

Biofilm Protocol Optimization For Pseudomonas aeruginosa. Introduction. Materials and Methods. Culture Media, Incubation Time, and Biofilm Measurement

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS

The Five Key Elements of a Successful Metabolomics Study

Controlled Release Drug Delivery from Hydrogels

COVER FEATURE HOW NANOTECHNOLOGY CAN REVOLUTIONIZE MEDICINE

A Review on Microdosing: Reduction in Cost & Time

Response Adjusted for Duration of Antibiotic Risk (RADAR) Scott Evans, Ph.D., M.S. Harvard University

leading the way in research & development

From the ADA and ABA Accessibility Guidelines for Buildings and Facilities

Vendor Selection: Identifying Effective Procedures & Strategies

Predicting Tissue Distribution & Clearance of Antibody Formats to Improve Selectivity of Targeted Therapies

Update on Real World Evidence Data Collection

COMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP)

Global Regulatory Perspective Workshop

Label-free, real-time live-cell assays for spheroids: IncuCyte bright-field analysis

Functional Assessment and Clinical Outcome

Bioreactors in tissue engineering

The Role of a Notified Body in Defining Risk Assessment for a Recombinant Protein Used in a Medical Device Case Study

Recent advances in tissue-engineered corneal regeneration

Soryong (Ryan) Chae Department of Biomedical, Chemical, and Environmental Engineering

The fundamentals of weld joint design

Materials and Methods. Introduction

Affinity Reagents: The Landscape and Affimer Technology Competitive Advantages

BIP Central Venous Catheter

Challenges in Antimicrobial Clinical Development. Axel Dalhoff & Heino Staß Institut für Klinische Pharmakologie Bayer AG, Wuppertal, D

Lili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences

Nanotechnology: A Brief History and Its Convergence with Medicine. Weston Daniel, PhD Director of Program Management

A full-service CRO with integrated early-stage capabilities

Reimbursement Strategy for Companion Diagnostics:

Skills Required by Pharmacologists and Physiologists in Today s Pharmaceu:cal Industry

February 28, Churchill Place Canary Wharf London E14 5EU United Kingdom

Workshop: Applying Exposure Science to Increase the Utility of Non-Animal Data in Efficacy and Safety Testing, 16 Feb. 2017

Session 2 summary Designs & Methods. Pairwise comparisons approach. Dose finding approaches discussed: Guiding principles for good dose selection

Artery-on-a-Chip: A Microfluidic Platform to Investigate Small Artery Function

Translational Medicine From Discovery to Health

Injectable modified release products

Alternativmethodezumknock-out Modell in der Arterioskleroseforschung: Sascha Meyer dos Santos

Stefano Monti. Workshop Format

Neue Technologien für die patientennahe personalisierte Diagnostik

DSM perspective on Innovation-driven growth

THE INNOVATION COMPANY HEALTH. Institute for Biomedicine and Health Sciences

1.1 WHAT MAKES POLYMERS SO INTERESTING?

PK/PD als Instrument zur Steuerung der klinischen Entwicklung von Antibiotika

Scale-up & scale-down between the two. worlds of shaken and stirred bioreactors

LUPAS Luminescent Polymers for in vivo Imaging of Amyloid Signatures

Samatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection

Transcription:

ENGINEERING 3D TISSUE SYSTEMS TO BETTER MIMIC HUMAN BIOLOGY Matthew Gevaert, Ph.D. CEO matt.gevaert@kiyatec.com

The Scientific Method is GREAT! Observation Hypothesis Test F = GMm r 2 Accept Hypothesis Reject Hypothesis

Except when it could kill you! Observation Hypothesis Test F = GMm r 2 This drug is toxic to humans Accept Hypothesis Reject Hypothesis

PHYSIOLOGY: Increasing Similarity / Increasing Relevance Human Human Biologic Models Paradigm Mammal Molecule 2D Environment 3D Environment Cell on Surface Cell in Tissue Multiple Cell Types In System Whole Organism BIOLOGICAL SCALE: Increasing Complexity / Increasing Relevance

PHYSIOLOGY: Increasing Similarity / Increasing Relevance Human People: Clinical Trials High Throughput: nonliving or 2D, static, 0-1 cell type High Content: 2D or 3D, static, 1 cell type Mammal Molecule 2D Environment 3D Environment Cell on Surface Cell in Tissue Multiple Cell Types In System Animal Studies Whole Organism BIOLOGICAL SCALE: Increasing Complexity / Increasing Relevance

Cells Are Alive and Interact Cells in 2D culture Cells in 3D culture Unnatural flat shape Natural spheroid shape

Cell Surface Interaction Contrast ~ 50%: Soluble Environment ~ 50%: Rigid Plastic or Mediating Layer Cell in 2D Very Little Cell to Cell biomerix.com Cell + Matrix + Soluble reinnervate.com nbsc.com Cell + Matrix + Soluble Cell in 3D Cell + Matrix + Soluble 3dbiotek.com

Superior Clinical Relevance of 3D Models Human 3D Cell Culture Mouse 2D Cell Culture Pearson Correlation Coefficient Most Relevant Human Human = 0.45 3D Human = 0.34 Mouse Human = 0.28 2D Human = 0.0 Least Relevant 3D: better than mouse! 2D: ZERO correlation! Ridky TW, Chow JM, Wong DJ, Khavari PA. Invasive threedimensional organotypic neoplasia from multiple normal human epithelia. Nature Medicine 16(12):1450-55, 2010.

Shape-Function Paradigms Shape Happens Maximize cell opportunity to form natural (in vivo) shape to maximize in vivo correlation Engineered Control Force cell shape to force cell function Kilian, (2010). PNAS 107(11): 4872-4877

Surface Topology On vs. In Surface fabrication of grooves, pillars, posts, pits, pyramids, etc. fabricated Cells grown on modified 2D surface Measurable cell response in many attributes Nikkhah, (2012), Biomaterials 33(21): 5230

Surface Topology On vs. In Topology on interior surfaces of 3D construct Cells grown in scaffold Measurable cell response in many attributes Kumar, (2012), Biomaterials 33(16): 4022

Size Does Matter - Edge Effect Cells respond to different matrix stiffness In many matrices internal stiffness varies with distance from edge Creates minimum real matrix dimensions to achieve natural (in vivo) cell micro-environment Mason BN, (2012). Acta Biomater Fraley, (2011), Nature Cell Bio 13(1): 5

Soluble Environment Effects Typical: feast vs. famine accepted trade-off Better: gradual replacement according to needs Wu, (2011), Biomed Microdevices 13(1): 131 Dhurjati, (2006), Tissue Engineering 12(11): 3045

Perfusion Over and Through Static

Perfusion Over and Through Static Perfusion over (flat) wyss.harvard.edu Over Dense Luminal Parallel Kim, (2012), Lab Chip 12: 2165

Perfusion Over and Through Static Perfusion over (flat) Perfusion through Over Dense Luminal Parallel wyss.harvard.edu Kim, (2012), Lab Chip 12: 2165 Through Porous Interstitial Perpendicular kiyatec.com Kumar, (2012), Biomaterials 33(16): 4022

The Need For Co-cultures Tang, (2004), Mol Canc Res 2:73

Traditional Co-Culture Models (2D) corning.com Uyama, (2002), J Hepatology 36: 590 Mixed Cell-to-cell contact Same Media Competition Segregated (Insert) Soluble factor mediated Different Media Non-competitive

Putting It All Together

Old Paradigm - in vitro Models Value High Throughput Acute Cost Minimization Synch w. Past Data Convenience 2D static monoculture Low Throughput Costs than 2D Data Disconnect Interesting but Impractical Complexity: 3D or perfusion or co-culture

Old Paradigm - Effectiveness Poorly Predictive Increasingly Expensive Only 12% of new drug candidates (NMEs) entering into clinical trials will successfully make it to launch 88% failure rate! Source: Nature Reviews Drug Disc 9, 203 (2010) Little to no complex (3D, ) cell-based data!

New Paradigm - in vitro Models Value Throughput but Relevance Cost & Value of Data Both Matter Oversimplified Use when can get away with 2D static monoculture Relevance for Throughput Overall Cost Reduction Managed complexity Use when value justifies cost 3D perfused co-culture

PHYSIOLOGY: Increasing Similarity / Increasing Relevance Human High Throughput: nonliving or 2D, static, 0-1 cell type High Content: 2D or 3D, static, 1 cell type High Relevance: 3D, perfused, 2+ cell types, biological feedback loops People: Clinical Trials Animal Studies Mammal Molecule 2D Environment 3D Environment Cell on Surface Cell in Tissue Multiple Cell Types In System Whole Organism BIOLOGICAL SCALE: Increasing Complexity / Increasing Relevance

Layered Approaches: Micro-fluidics Example research system: Wyss Organ On A Chip 2D? 3D? mm dimensions Barrier / lumen emphasis Perfused Focus on over flat Co-culture Segregated & mixed Now Commercialized passive plates; single organ models Future Linked system models

Layered Approaches: Meso-fluidics Example commercial platform: KIYATEC 3DKUBE Easy loading and removal of cellscaffold construct 3D mm dimensions Tissue emphasis Perfused Focus on through Co-culture Segregated & mixed Now Commercialized pumped platforms; single organ models Future Linked system models; crossover to regen. med. / tissue eng.

Engineered 3D environments for living, human cells in laboratory culture Cell + Matrix + Soluble Cell + Matrix + Soluble Accurate recreation of living, interacting physiologic systems in human being best patient therapy chosen first fewer drug clinical trial failures RRR of animal research meaningful output Cell + Matrix + Soluble better cell therapy process harnessed biology (regen med) biomanufacturing (tissue eng)